- Home
- ETON vs ALMS Comparison
ETON vs ALMS Comparison
Compare ETON & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ALMS
- Stock Information
- Founded
- ETON 2017
- ALMS 2021
- Country
- ETON United States
- ALMS United States
- Employees
- ETON N/A
- ALMS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- ETON Health Care
- ALMS
- Exchange
- ETON Nasdaq
- ALMS NYSE
- Market Cap
- ETON 428.5M
- ALMS 402.6M
- IPO Year
- ETON 2018
- ALMS 2024
- Fundamental
- Price
- ETON $13.75
- ALMS $3.30
- Analyst Decision
- ETON Strong Buy
- ALMS Strong Buy
- Analyst Count
- ETON 3
- ALMS 7
- Target Price
- ETON $29.67
- ALMS $24.50
- AVG Volume (30 Days)
- ETON 457.7K
- ALMS 910.9K
- Earning Date
- ETON 08-07-2025
- ALMS 08-12-2025
- Dividend Yield
- ETON N/A
- ALMS N/A
- EPS Growth
- ETON N/A
- ALMS N/A
- EPS
- ETON N/A
- ALMS N/A
- Revenue
- ETON $48,327,000.00
- ALMS $17,389,000.00
- Revenue This Year
- ETON $103.21
- ALMS N/A
- Revenue Next Year
- ETON $51.34
- ALMS N/A
- P/E Ratio
- ETON N/A
- ALMS N/A
- Revenue Growth
- ETON 40.88
- ALMS N/A
- 52 Week Low
- ETON $3.19
- ALMS $2.76
- 52 Week High
- ETON $21.48
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- ETON 26.60
- ALMS N/A
- Support Level
- ETON $13.09
- ALMS N/A
- Resistance Level
- ETON $14.18
- ALMS N/A
- Average True Range (ATR)
- ETON 0.78
- ALMS 0.00
- MACD
- ETON -0.23
- ALMS 0.00
- Stochastic Oscillator
- ETON 8.78
- ALMS 0.00
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.